Perrigo Co. Plc (PRGO)
14.26
+0.24
(+1.71%)
USD |
NYSE |
Oct 02, 16:00
14.28
+0.02
(+0.14%)
Pre-Market: 20:00
Perrigo Enterprise Value : 5.037B for Oct. 2, 2026
Enterprise Value Chart
Historical Enterprise Value Data
| Date | Value |
|---|---|
| October 02, 2026 | 5.037B |
| October 01, 2026 | 5.004B |
| September 30, 2026 | 5.106B |
| September 29, 2026 | 5.140B |
| September 28, 2026 | 5.153B |
| September 25, 2026 | 5.198B |
| September 24, 2026 | 5.095B |
| September 23, 2026 | 4.979B |
| September 22, 2026 | 5.044B |
| September 21, 2026 | 5.019B |
| September 18, 2026 | 4.940B |
| September 17, 2026 | 4.929B |
| September 16, 2026 | 4.937B |
| September 15, 2026 | 4.940B |
| September 14, 2026 | 4.952B |
| September 11, 2026 | 4.954B |
| September 10, 2026 | 4.944B |
| September 09, 2026 | 5.048B |
| September 08, 2026 | 5.081B |
| September 04, 2026 | 5.128B |
| September 03, 2026 | 5.038B |
| September 02, 2026 | 5.069B |
| September 01, 2026 | 5.060B |
| August 31, 2026 | 5.090B |
| August 28, 2026 | 5.067B |
| Date | Value |
|---|---|
| August 27, 2026 | 5.052B |
| August 26, 2026 | 5.106B |
| August 25, 2026 | 5.067B |
| August 24, 2026 | 5.038B |
| August 21, 2026 | 5.035B |
| August 20, 2026 | 4.959B |
| August 19, 2026 | 4.995B |
| August 18, 2026 | 4.858B |
| August 17, 2026 | 4.837B |
| August 14, 2026 | 4.868B |
| August 13, 2026 | 4.839B |
| August 12, 2026 | 4.819B |
| August 11, 2026 | 4.841B |
| August 10, 2026 | 4.812B |
| August 07, 2026 | 4.840B |
| August 06, 2026 | 4.798B |
| August 05, 2026 | 4.900B |
| August 04, 2026 | 4.554B |
| August 03, 2026 | 4.540B |
| July 31, 2026 | 4.461B |
| July 30, 2026 | 4.489B |
| July 29, 2026 | 4.506B |
| July 28, 2026 | 4.488B |
| July 27, 2026 | 4.465B |
| July 24, 2026 | 4.458B |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Enterprise Value Benchmarks
| ANI Pharmaceuticals, Inc. | 1.893B |
| Corcept Therapeutics, Inc. | 12.24B |
| Veru, Inc. | 19.69M |
| Johnson & Johnson | 644.86B |
| Eli Lilly & Co. | 1.122T |
Enterprise Value Related Metrics
| Net Income (Quarterly) | 88.50M |
| Revenue (Quarterly) | 1.023B |
| Total Expenses (Quarterly) | 934.30M |
| EPS Diluted (Quarterly) | 0.5337 |
| Gross Profit Margin (Quarterly) | 30.73% |
| Profit Margin (Quarterly) | 8.65% |
| Earnings Yield | -87.73% |
| Operating Earnings Yield | 13.43% |
| Normalized Earnings Yield | -24.12 |